Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

The Health Services industry as a whole closed the day down 0.3% versus the S&P 500, which was up 0.1%. Laggards within the Health Services industry included

American Caresource Holdings

(

ANCI

), down 8.2%,

Pro-Dex

(

PDEX

), down 3.3%,

Vision-Sciences Inc (DE

(

VSCI

), down 2.5%,

LeMaitre Vascular

(

LMAT

), down 2.4% and

Kips Bay Medical

(

KIPS

), down 2.0%.

TheStreet Ratings Group would like to highlight 3 stocks that pushed the industry lower today:

LeMaitre Vascular

(

LMAT

) is one of the companies that pushed the Health Services industry lower today. LeMaitre Vascular was down $0.18 (2.4%) to $7.45 on heavy volume. Throughout the day, 76,643 shares of LeMaitre Vascular exchanged hands as compared to its average daily volume of 13,000 shares. The stock ranged in price between $7.15-$7.69 after having opened the day at $7.64 as compared to the previous trading day's close of $7.63.

LeMaitre Vascular, Inc., together with its subsidiaries, develops, manufactures, and markets medical devices and implants for the treatment of peripheral vascular disease worldwide. LeMaitre Vascular has a market cap of $120.9 million and is part of the health care sector. Shares are down 3.5% year-to-date as of the close of trading on Thursday. Currently there are 4 analysts who rate LeMaitre Vascular a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates

LeMaitre Vascular

as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and disappointing return on equity.

Highlights from TheStreet Ratings analysis on LMAT go as follows:

  • LMAT's revenue growth has slightly outpaced the industry average of 3.3%. Since the same quarter one year prior, revenues slightly increased by 8.9%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
  • LMAT has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 2.64, which clearly demonstrates the ability to cover short-term cash needs.
  • Compared to its closing price of one year ago, LMAT's share price has jumped by 27.56%, exceeding the performance of the broader market during that same time frame. Setting our sights on the months ahead, however, we feel that the stock's sharp appreciation over the last year has driven it to a price level which is now relatively expensive compared to the rest of its industry. The implication is that its reduced upside potential is not good enough to warrant further investment at this time.
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income has significantly decreased by 124.5% when compared to the same quarter one year ago, falling from $0.85 million to -$0.21 million.
  • The company's current return on equity has slightly decreased from the same quarter one year prior. This implies a minor weakness in the organization. Compared to other companies in the Health Care Equipment & Supplies industry and the overall market, LEMAITRE VASCULAR INC's return on equity significantly trails that of both the industry average and the S&P 500.

You can view the full analysis from the report here:

LeMaitre Vascular Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

At the close,

Vision-Sciences Inc (DE

(

VSCI

) was down $0.03 (2.5%) to $1.15 on light volume. Throughout the day, 3,300 shares of Vision-Sciences Inc (DE exchanged hands as compared to its average daily volume of 70,200 shares. The stock ranged in price between $1.09-$1.18 after having opened the day at $1.18 as compared to the previous trading day's close of $1.18.

Vision-Sciences, Inc., together with its subsidiaries, engages in the design, development, manufacture, and marketing of endoscopy products. The company operates in two segments, Medical and Industrial. Vision-Sciences Inc (DE has a market cap of $53.3 million and is part of the health care sector. Shares are up 18.0% year-to-date as of the close of trading on Thursday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates

Vision-Sciences Inc (DE

as a

sell

. The company's weaknesses can be seen in multiple areas, such as its poor profit margins, generally disappointing historical performance in the stock itself and unimpressive growth in net income.

Highlights from TheStreet Ratings analysis on VSCI go as follows:

  • The gross profit margin for VISION-SCIENCES INC is currently lower than what is desirable, coming in at 31.02%. It has decreased from the same quarter the previous year. Along with this, the net profit margin of -48.08% is significantly below that of the industry average.
  • In its most recent trading session, VSCI has closed at a price level that was not very different from its closing price of one year earlier. This is probably due to its weak earnings growth as well as other mixed factors. The fact that the stock is now selling for less than others in its industry in relation to its current earnings is not reason enough to justify a buy rating at this time.
  • The change in net income from the same quarter one year ago has exceeded that of the Health Care Equipment & Supplies industry average, but is less than that of the S&P 500. The net income has decreased by 15.8% when compared to the same quarter one year ago, dropping from -$2.07 million to -$2.40 million.
  • VISION-SCIENCES INC's earnings per share declined by 25.0% in the most recent quarter compared to the same quarter a year ago. This company has not demonstrated a clear trend in earnings over the past 2 years, making it difficult to accurately predict earnings for the coming year. During the past fiscal year, VISION-SCIENCES INC continued to lose money by earning -$0.16 versus -$0.22 in the prior year.
  • Net operating cash flow has increased to -$1.37 million or 44.79% when compared to the same quarter last year. The firm also exceeded the industry average cash flow growth rate of 7.82%.

You can view the full analysis from the report here:

Vision-Sciences Inc (DE Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

American Caresource Holdings

(

ANCI

) was another company that pushed the Health Services industry lower today. American Caresource Holdings was down $0.25 (8.2%) to $2.80 on average volume. Throughout the day, 11,134 shares of American Caresource Holdings exchanged hands as compared to its average daily volume of 8,000 shares. The stock ranged in price between $2.80-$3.07 after having opened the day at $3.05 as compared to the previous trading day's close of $3.05.

American CareSource Holdings, Inc. provides access to a network of ancillary healthcare service providers in the United States. American Caresource Holdings has a market cap of $19.0 million and is part of the health care sector. Shares are up 86.0% year-to-date as of the close of trading on Thursday.

TheStreet Ratings rates

American Caresource Holdings

as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and poor profit margins.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Highlights from TheStreet Ratings analysis on ANCI go as follows:

  • AMERICAN CARESOURCE HLDGS's earnings per share declined by 25.0% in the most recent quarter compared to the same quarter a year ago. The company has suffered a declining pattern earnings per share over the past two years. During the past fiscal year, AMERICAN CARESOURCE HLDGS reported poor results of -$0.66 versus -$0.54 in the prior year.
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Health Care Providers & Services industry. The net income has decreased by 24.7% when compared to the same quarter one year ago, dropping from -$1.15 million to -$1.44 million.
  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Health Care Providers & Services industry and the overall market, AMERICAN CARESOURCE HLDGS's return on equity significantly trails that of both the industry average and the S&P 500.
  • The gross profit margin for AMERICAN CARESOURCE HLDGS is currently extremely low, coming in at 1.28%. It has decreased from the same quarter the previous year. Along with this, the net profit margin of -28.65% is significantly below that of the industry average.
  • The revenue fell significantly faster than the industry average of 16.7%. Since the same quarter one year prior, revenues fell by 34.1%. The declining revenue appears to have seeped down to the company's bottom line, decreasing earnings per share.

You can view the full analysis from the report here:

American Caresource Holdings Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.